| Morgera et al. 2004 [27] | Morgera et al. 2006 [30] | Haase et al. 2007 [31] | Chelazzi et al. 2016 [32] | Kade et al. 2016 [34] | Villa et al. 2017 [33] | |
---|---|---|---|---|---|---|---|
Study design | Prospective single-center pilot trial | Prospective RCT | Prospective RCT | Double-blind, crossover RCT | Retrospective, observational | Retrospective, single center | Observational prospective multicenter study |
Study population (n) | 16 septic shock patients | 24 patients with sepsis-induced AKI | 30 septic patients with AKI | 10 septic patients with AKI | 16 patients with Gram-negative sepsis | 28 patients with septic shock | 38 patients with septic shock and AKI |
Prescribed dose | Intermittent HP-HF over 5Â days for 12Â h/day alternating with conventional HF (12Â h) | CVVH (UF 1Â L/h) vs CVVH (UF 2.5Â L/h) vs CVVHD (dialysate flow rate of 1Â L/h) vs CVVHD (dialysate flow rate of 2.5Â L/h) | HCO vs conventional HF | 4Â h of HCO-IHD and 4Â h of HF-IHD | HCO 35Â ml/kg/h vs CVVHDF 45Â ml/kg/h | HCO-CVVHDF | HCO-CVVHD for 72Â h |
Results | High IL-6 elimination | Increasing UF volume or dialysate flow led to a significant increase in IL-1ra and IL-6 clearance rates (p < 0.00001) | Significant reduction in VP dose in the HCO group (p = 0.0002) Clearance rates for IL-6 and IL-1ra were significantly higher in the HCO group (p < 0.0001) | Greater decrease in plasma IL-6 levels (p = 0.05), plasma IL-8 (p = 0.02) and plasma IL-10 (p = 0.04) in the HCO group | ICU mortality rates were 37.5 and 87.5% for HCO and HF groups, respectively (p = 0.03) ICU LOS: 16 and 9 days (HCO- and HF-group; p = 0.03). Improvement of hemodynamics in the HCO group (p < 0.03) | Significant reduction in IL-10 and IL-12 levels | Significant reduction in circulating levels of TNFα and IL-6 among survivors |
Safety or S/E | High cumulative 12-h protein loss (7.60 g; IQR 6.2–12.0) | High protein and albumin losses with 2.5-L/h HF mode | None | Albumin loss of 7.7 g in the HCO group vs < 1.0 g (p < 0.01) | – | – | – |